New hope for advanced GI cancers: first human trial launches

NCT ID NCT07263594

Recruiting now Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called DB-1324 in people with advanced or spreading stomach, bowel, or other gastrointestinal cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 127 participants will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm Digestive System Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL CANCER

Contacts and locations

Locations

AUS01-0
RECRUITING

Nedlands, Western Australia, 6009, Australia
AUS02-0
RECRUITING

Randwick, New South Wales, 2031, Australia
AUS03-0
RECRUITING

South Brisbane, Queensland, 4101, Australia
CHN01-0
RECRUITING

Beijing, 100142, China
CHN04-0
RECRUITING

Beijing, 102206, China
USA01-0
RECRUITING

Huntersville, North Carolina, 28078, United States
USA02-0
RECRUITING

Grand Rapids, Michigan, 49546, United States
USA03-0
RECRUITING

Cincinnati, Ohio, 45219, United States
USA05-0
RECRUITING

Port Saint Lucie, Florida, 34952, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.